Chemours Trades at 0.31x Sales and 7.2x Forward P/E, Eyes 2026 PFAS Settlement
Chemours trades at 0.31x sales versus the 1.08x industry average and carries a forward P/E of 7.2, reflecting deep undervaluation driven by PFAS litigation overhang. Opteon refrigerants and Advanced Performance Materials segments are supported by data center and semiconductor demand, with PFAS settlement visibility in 2026 as a potential rerating catalyst.
1. Valuation Overview
Chemours is priced at 0.31x sales compared with an industry average of 1.08x, carries a forward P/E of 7.2 and a trailing P/E of 61.8, signaling substantial market pessimism. Hedge fund ownership declined from 48 portfolios in Q2 to 42 in Q3, highlighting reduced institutional conviction.
2. Growth Drivers
The Opteon refrigerants business benefits from accelerating cooling requirements in data centers, while the Advanced Performance Materials segment capitalizes on expanding semiconductor, industrial and specialty chemical markets to drive revenue and margin expansion.
3. PFAS Litigation Outlook
Ongoing PFAS liability concerns have weighed on sentiment, but anticipated settlement visibility in 2026 could remove a major overhang, unlocking rerating potential if legal risks are resolved or substantially narrowed.